Comparison of Antimicrobial Coated Ureteral Stents With Non-coated Stents

A Randomized Controlled Trial Comparing Antimicrobial Coated (Silver Sulfadiazine) Ureteral Stents With Non-coated Stents

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02266368

Enrollment

110

Registered

2014-10-17

Start date

2014-10-31

Completion date

2016-09-30

Last updated

2016-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Quality of Life

Keywords

Ureteral stents, Double J stent, Antimicoreal coated stent, USSQ, UTI

Brief summary

This study will be conducted to compare the efficacy of antimicrobial coated ureteral stent with non-coated stents in prevention of UTI in patients with ureteral stents

Detailed description

The efficacy of antimicrobial coated of ureteral stent with silver sulphadiazine in prevention of UTI in patients with ureteral stents will be studied by comparining the results of urine and stent cultures with patients who had non-coated ureteral stents. The impact of antimicrobeal stent coating on patients' quality of life will be evaluated with comparing the scores of ureteral stent symptom questionnaire between both groups.

Interventions

DEVICEAntimicrobeal coated stents

Patients in the intervention arm will undergo placement of (Silver Sulphdiazine) antimicrobeal coated stents

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Patients who will undergo ureteral stent placement

Exclusion criteria

* Patients allergic to sulpha containing medications * Ureteral stent insertion for infected hydronephrosis * Patients who developed septic complications requiring antibiotic treatment after stent placement * Patients who need bilateral stents * Patients with chronic kidney disease grade IV and V (GFR \<30ml/min) * Immunocompromised patients as those with malignancy or organ transplantation.

Design outcomes

Primary

Measure	Time frame	Description
Incidence of urinary tract infection (UTI)	up to 3 months	UTI will be diagnosed with urine and stent culture of stent removal

Secondary

Measure	Time frame	Description
Quality of life	up to 3 months	The impact of stent coating on quality of life will be assissed with ureteral stent symptom questionnaire (USSQ)

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026